the adverse chemical influences of clostridia...
TRANSCRIPT
The Adverse Chemical Influences of Clostridia Bacterial Toxins and Chronic Health Problems –
Beyond Common GI Issues
Copyright© 2015, Kurt N. Woeller, D.O., Tracy Tranchitella, N.D., and Educational Resource Association. This material may not be reprinted,
distributed or used without permission.
Support Documents For Module #5
• Clostridia Antibiotic Protocol – examples (pdf)
• Clostridia Natural Remedy Protocol – examples (pdf)
• Clostridia Treatment Program – patient handout
• General Considerations for Organic Acids Testing for Clostridia Related Problems (pdf).
• Overview of Common Probiotics (pdf)
• Taking Probiotic Suggestions (pdf)
• Fecal Transplant Donor Test Recommendations (pdf)
• Lecture slides (pdf) + Lecture slides - note taking (pdf)
YOUR LOGO
Lecture Overview• Clostridia bacteria and various health problems, including
the pathogenicity of C. difficile.
• Clostridia bacteria toxins and how they negatively effect the brain and nervous system.
• HPHPA & 4-cresol (and potentially others) as the main culprits for dopamine converting enzyme inhibition.
• The toxic problems of excess dopamine
• A deeper understanding of probiotics – specific to clostridia bacteria (helpful against candida too).
• Various treatment options:• Antibiotic and botanical remedies
• Fecal Microbiota Transplant (FMT) information
YOUR LOGO
Clinical Usefulness of Clostridia Treatments
• Schizophrenia
• Psychosis
• Depression
• Chronic fatigue
• Tics, Tourette’s
• Autism, ADD/ADHD
• Autoimmune, i.e. RA
• Obsessive compulsive disorder.
• Seizure disorders
• Gastrointestinal disorders, diarrhea, constipation.
YOUR LOGO
Nutritional Neuroscience 2010 Vol 13 No 3: 1-10
Great Plains Laboratory – ‘Resource’ section, Articles
YOUR LOGO
Effect of anti-Clostridia therapy
on urine excretion of HPHPA* in
young woman with acute
psychosis-auditory
hallucinations
patient normals
During acute 7489 0-150
psychosis
After treatment 673 0-150
( depressed but no
psychosis)
*mmol/mol creatinine
YOUR LOGO
Clostridium difficile
YOUR LOGO
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N
Engl J Med. 2015;372:825-834
• The Centers for Disease Control estimates that there were 453,000 documented cases of Clostridium difficile infection (CDI) in the United States in 2011 leading to 29,300 deaths.
• Between 10% and 30% of people who have an initial episode of CDI will develop at least one recurrence. NOTE: Approximately 20% recurrence rate.
• On the basis of the number of incident cases found in 2011, 45,300-135,900 people developed recurrent CDI.
YOUR LOGO
Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age. Med Dosw
Mikrobiol; 2010;62(1):77-84 (Poland)
• 178 fecal samples of children aged 2 months to 2 years, hospitalized in 2003-2006, were examined for the presence of toxin A/B of C. difficile.
• Toxigenicity of strains was confirmed using PCR
• Susceptibility to antimicrobials was determined
• The percentage of children infected with C. difficile was 68.6%.
• All strains were susceptible to Vancomycin and Metronidazole (Flagyl).
YOUR LOGO
Inflammatory Bowel Secondary to C. Difficile
• In 1977, it was established that Pseudomembranous colitis was caused by toxins produced from Clostridium difficile.
• Toxin A (enterotoxin) and toxin B (cytotoxin) are produced by C. difficile and are involved in the disease process.
• Pseudomembranous colitis is frequently nosocomial with an increased risk of spread among hospitalized patients.• The C. difficile spores contaminate the patient's immediate
environment and are spread to other patients on the hands of healthcare workers and medical equipment brought into the room.
• All groups of antibiotics like cephalosporin, penicillin, clindamycin and ampicillin are commonly associated with pseudomembranous colitis.
YOUR LOGO
Brush Border, Villi and Tight Junction Damage
Toxin A Toxin B
YOUR LOGO
Toxin A & Toxin B
• These two toxins are the main virulence factors related to mucosal damage from C. difficile.• There are other strains of Clostridia difficile that produce
4-cresol and not A and B toxin.
• Toxins A & B lead to digestive tract inflammation, i.e. Pseudomembranous colitis or clostridia difficile associated diarrhea (CDAD).
• Toxin A & Toxin B are both capable of causing mucosal damage (Kuehne SA, Cartman ST, Heap JT, Kelly ML,
Cockayne A, Minton NP; October 2010. "The role of toxin A and toxin B in Clostridium difficile infection". Nature 467 (7316): 711–3).
YOUR LOGO
Toxin A
• Categorized as an Enterotoxin:• Toxin released by microorganisms that target the
intestines.
• It functions by changing host cell metabolism disrupting actin and tight junction function.• This leads to cell death, mucosal damage, and fluid
secretions.
• Considered to be the main cause of CDAD as it damages intestinal villi and the brush border.
• Can also lead to the severe ulcerations seen in Pseudomembranous colitis.
YOUR LOGO
Toxin B• Categorized as an Cytotoxin:
• A chemical that is toxic to cells, i.e. certain immune cells, venom (i.e. snake, spider).
• Causes major cellular disruption by interfering with signaling pathways, tight junction formation, cytoskeleton of cell, and derangement of overall cell structure.
• It is a major virulence factor of C. difficile opening up tight junctions which leads to vascular swelling and hemorrhaging.
• Induces Tumor Necrosis Factor-α and other pro-inflammatory cytokines which can have local and systemic effects.
YOUR LOGO
Inflammatory membrane (Pseudomembrane) overlying site of mucosal injury
YOUR LOGO
What are Clostridium Bacteria?
• Obligate anaerobes:• microorganisms that are killed by
normal atmospheric oxygen (O2).
• Obligate = strictly, adhered to
• 5 main species known to cause disease: C. botulinum, C. difficile, C. perfringens, C. tetani, and C. sordellii.
• Clostridium spores – reproductive cell of clostridium. Has thick wall and can resist volatile environments. Helps with defense.
• About 100 species of Clostridia can inhabit GI tract.
Clostridium bacteria
YOUR LOGO
Spore formation – major factor for Clostridia bacteria recurrence
• Recurrences occur after use of Metronidazole and/or Vancomycin (vancocin).
• Forms spores that are highly resistant to heat and antibiotics.
• Spores not killed by common disinfectants like alcohol hand wipes - may actually help spores spread.
• Only bleach kills spores
• Carriers without symptoms may spread spores
YOUR LOGO
YOUR LOGO
Other Toxins of Clostridia Bacteria
YOUR LOGO
Structure of 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA)
HO
CHOHCH2COOH123
1
23
4
5 6
Phenyl group
Hydroxyl group
Propionic acid
YOUR LOGO
HPHPA• Known producers of HPHPA: C. botulinum, C.
sporogenes (similar to C. botulinum, but doesn’t contain the neurotoxin), and C. caloritolerans.
• Severe botulinum infection:• Sudden onset weakness (arms, legs, chest), trouble
seeing and speaking, and eventual flaccid paralysis.
• Some cases of food borne C. botulinum can have mild symptoms with people seeking no medical attention.
• Autism-Spectrum Disorders (often seen with high HPHPA):• little to no speech
• low muscle tone
YOUR LOGO
Distribution of values for HPHPA Clostridia metabolite in urine samples of male infants,
control boys, and boys with autism.
Control
infants
Control
boys
2-13 years
Autistic
Boys
2-13
years
YOUR LOGO
Critical effect of intestinal bacteria on neurotransmitters
Organic acids test
Organic acids test
Organic acids test
YOUR LOGO
Structure of 4-cresol (methylphenol)
HOCH31
2
3
4
5 6
Phenyl group
Hydroxyl group
YOUR LOGO
4-Cresol
• Major producer is C. difficile
• No other species of clostridia are known to produce this chemical.
• High toxicity known to cause circulatory collapse and death.
• Known to have growth suppressing effects in animals.
• Signs of acute toxicity – hypoactivity, salivation, tremors, and convulsions.
YOUR LOGO
Critical effect of intestinal bacteria on neurotransmitters
Organic acids test
Organic acids test
Organic acids test
YOUR LOGO
• Clostridium difficile is an important nosocomial pathogen, resulting in antibiotic-associated disease ranging from mild diarrhea to the life-threatening pseudomembranous colitis. Upon antibiotic exposure, it is believed that the normal bowel microflora of patients is disrupted, allowing C. difficile to proliferate.
• C. difficile is among only a few bacteria able to ferment tyrosine to p-cresol, a phenolic compound that is toxic to other microbes via its ability to interfere with metabolism.
• Therefore, the ability of different C. difficile strains to produce and tolerate p-cresol may play an important role in the development and severity of C. difficile-associated disease. In this study, it was demonstrated that two C. difficile hypervirulent 027 strains (Stoke Mandeville and BI-16) are more tolerant to p-cresol than other C. difficile strains including 630, CF4 and CD196. Surprising, it was shown that Clostridium sordellii also has a high tolerance to p-cresol, suggesting an overlap in the tolerance pathways in these clostridia species.
Dawson LF, et.al. “Assessing the role of p-cresol tolerance in Clostridium difficile” J Med Microbiol. 2008 Jun
YOUR LOGO
Goodhart PJ, DeWolf WE Jr, Kruse LI. Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol and related
alkylphenols. Biochemistry. 1983 Jun 21; 22(13):3091-6.
• A wide range of phenols, including p-cresol, a major Clostridia metabolite, are strong inhibitors of dopamine-beta-hydroxylase which converts dopamine to norepinephrine.
YOUR LOGO
Goodhart PJ, DeWolf WE Jr, Kruse LI. Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol (4-cresol) and related
alkylphenols. Biochem. 1983 Jun 21; 22(13):3091-6.
• Most importantly, the reaction is irreversible and the p-cresol is incorporated into the enzyme active site so that further enzyme activity is destroyed.
YOUR LOGO
“Microbiota Modulate Behavioral and Physiological Abnormalities Associated with Neurodevelopmental Disorders” - Elaine Y. Hsiao, et. al.
• Demonstrate GI barrier defects and microbiota alterations in the immune activation (MIA) mouse model that is known to display features of ASD.
• Oral treatment of MIA with the human commensal Bacteroides fragiliscorrects gut permeability, alters microbial composition, and ameliorates defects in communicative, stereotypic, anxiety-like and sensorimotor behaviors. MIA display an altered serum metabolomic profile (4-ethylphenylsulphate), and B. fragilis modulates levels of several metabolites.
• Treating naive mice with a metabolite that is increased by MIA and restored by B. fragilis causes certain behavioral abnormalities, suggesting that gut bacterial effects on the host metabolome impact behavior.
“Taken together, these findings support a gut-microbiome-brain connection in a mouse model of ASD and identify a
potential probiotic therapy for GI and particular behavioral symptoms in human neurodevelopmental disorders.”
December 5, 2013
YOUR LOGO
The researchers further dissected what was going on by screening for chemicals in the blood that differed between autistic and wild-type mice. One compound, 4-ethylphenylsulphate (4EPS), stood out:
1. It was found at levels 46 times higher in autistic mice.
2. Injecting 4EPS into wild-type mice resulted in autism-like behaviors.
4EPS – Is similar in chemical structure to 4-Cresol which is known to inhibit Dopamine Beta-
Hydroxylase.
4-ethylphenylsulphate
YOUR LOGO
Elevated HPHPA and High HVA in 6 year Old Chinese ASD Child
HVA/VMA = 4.10
YOUR LOGOHVA/VMA = 2.58
Male - Before Treatment (depression)
YOUR LOGO
Male After Treatment (no depression)
HVA/VMA = 1.38
YOUR LOGO
3-indole-acetic acid
YOUR LOGO
3-Indoleacetic acid
• High 3-indoleacetic acid in urine is a byproduct of: C. stricklandii, C. lituseburense, C. subterminale, and C. putrefaciens.
• Very high amounts of this metabolite derived from tryptophan might indicate a depletion of tryptophan needed for other physiological functions.
YOUR LOGO
Phenyllactic Acid
YOUR LOGO
Phenyllactic Acid
• Very high amounts of phenyllactic acid are found in the rare genetic disease phenylketonuria (PKU).
• Moderate amounts of phenyllactic acid may be due to gastrointestinal overgrowth of the intestine of the following Clostridia bacteria: C. sordellii, C. stricklandii, C. mangenoti, C. ghoni, and C. bifermentans.
• C sordellii is usually considered a non-pathogen except in immunocompromised people, but has been implicated in catastrophic infectious gynecologic illnesses among women of childbearing age.
• The other species have rarely or never been reported to be pathogenic.
YOUR LOGO
4-Hydroxyphenylacetic acid
YOUR LOGO
4-Hydroxyphenylacetic acid • High 4-hydroxyphenylacetic acid is associated with small intestinal
bacteria overgrowth due to its production by the following Clostridia bacteria: C. difficile, C. stricklandii, C. lituseburense, C. subterminale, C. putrefaciens, and C. propionicum.
• It is likely that 4-hydroxyphenylacetic is also an inhibitor of dopamine-beta-hydroxylase.
• Elevated values are common in celiac disease and cystic fibrosis, and have also been reported in transient lactose intolerance, Giardia infection, ileal resection, septicemia, and projectile vomiting.
• The elevations of 4-hydroxyphenylacetic acid in celiac disease and cystic fibrosis are so prevalent that involvement of these Clostridia bacteria may play a role in these illnesses.
• In C. difficile infections, 4-hydroxyphenylacetic acid is utilized by this bacteria to produce 4-cresol.
YOUR LOGO
YOUR LOGO
YOUR LOGO
YOUR LOGO
Structure of 2-hydroxyhippuric acid - metabolite of aspartame (Nutrasweet®), aspirin, foods, additives
HO
CONHCH2COOH1
2
3
4
5 6
Phenyl group
Hydroxyl groupglycine
salicylate
YOUR LOGO
Structure of aminophenol - major acetaminophen metabolite
HO1
2
3
4
5 6
Phenyl group
Hydroxyl group
NH2
YOUR LOGO
YOUR LOGO
What About DHPPA?
• 3,4-dihydroxyphenylpropionic acid (DHPPA) is a marker for beneficial bacteria in the gastrointestinal tract such as Lactobacilli, Bifidobacteria, and E. coli – the exception is Clostridia orbiscindens which converts certain flavanoids (i.e., parsley, thyme, celery) into DHPPA.
• The quantity of C. orbiscindens in the gastrointestinal tract is negligible (approximately 0.1% of the total bacteria) compared to the predominant flora.
• DHPPA is an antioxidant that lowers cholesterol, reduces pro-inflammatory cytokines, and protects against pathogenic bacteria.
YOUR LOGO
YOUR LOGO
16050–16055 | PNAS | September 20, 2011 | vol. 108 | no. 38
YOUR LOGO
“Gut Microbiome and Brain-Gut Axis in Autism — Aberrant Development of Gut-
Brain Communication and Reward Circuitry” Intech, 2013
Elizabeth M. Sajdel-Sulkowska1 and Romuald Zabielski2[1] Dept. Psychiatry Harvard Medical School and BWH, USA[2] DDept. Physiological Sciences, Warsaw University of Life Sciences, Poland
YOUR LOGO
• Animal studies have also shown that stress can change the composition of the microbiome, where the changes are associated with increased vulnerability to inflammatory stimuli in the gut.
• Stress is known to inhibit gut contraction, one of the crucial defense strategies against bacterial colonization of gut mucosa.
• Early psychological trauma of maternal separation resulted in persistent mucosal barrier dysfunction in neonatal rats, including host defense to luminal bacteria, by mechanisms involving peripheral CRH receptors.
Stress
YOUR LOGO
• Evidence indicates that the Vagus Nerve is involved in immunomodulation by attenuating the production of pro-inflammatory cytokines in experimental models of inflammation.
• The microbiome also plays an important role in anxiety-like and depressive behaviors as the effects are diminished in vagatomized animals.
• Suggests either the direct communication between the bacteria and the brain or through the brain-gut axis.
Vagus Nerve and Immune Function
YOUR LOGO
• Oral antibiotics disrupt the microbiome and favor environment for opportunistic bacteria.
• Clostridium tetani produces a potent neurotoxin, tetanus neurotoxin (TeNT), that is transported by the vagus nerve from the GI to the CNS.
• Inhibitory neurons that release the neurotransmitter GABA are a preferred target for tetanus neurotoxins - and the Purkinje cells of the cerebellum, which often appear highly abnormal in autistic individuals, are inhibitory neurons that release GABA.
Vagus Nerve Transport of Neurotoxins
YOUR LOGO
YOUR LOGO
Detrimental Effects of Excess Dopamine
• Overstimulation of dopamine tracts
• Substitution of dopamine into norepinephrine tracts and sympathetic nervous system.
• Damage to neurons producing excess dopamine due to oxidative damage of abnormal dopamine metabolites.
• Depletion of glutathione in brain making it susceptible to other toxic chemicals.
YOUR LOGO
Linan Chen, et al(2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative
stress in mice. J. Neurosci. 28, 425–433
• Dopamine is a very reactive molecule (particularly the cytosolic dopamine) compared with other neurotransmitters, and dopamine degradation naturally produces oxidative species.
• More than 90% of dopamine in dopamine neurons is stored in abundant terminal vesicles and is protected from degradation.
• However, a small fraction of dopamine is cytosolic, and it is the major source of dopamine metabolism and presumed toxicity – leading to glutathione depletion.
YOUR LOGO
Toxicity of excess dopamine
Homovanillic acid (HVA)Dihydroxyphenylacetic(DOPAC)
Cycled thousands of times
YOUR LOGO
Fig. 2. The tricarboxylic acid cycle during high levels of propionic acid. Propionic acid, presumably derived from Clostridia spp., is metabolized to propionyl-CoA using acetyl-CoA. Propionyl-CoA is further metabolized into methylmalonyl-CoA, which enters the tricarboxylic acid cycle as succinyl-CoA. Succinyl-CoA inhibits the first and fourth enzyme in the tricarboxylic acid cycle. In this manner, propionic acid may ‘short circuit’ the
tricarboxylic acid cycle, thereby reducing the production of nicotinamide adenine dinucleotide (NADH). This decrease in NADH is hypothesized to cause the decrease in complex I activity measured in the patients with
consistent elevations in short and long acyl-carnitines (CESLAC)
From: Gastrointestinal dysfunction in autism spectrum disorders: the role of the mitochondria and the enteric microbiome (2015).
YOUR LOGO
Treatment Options for Clostridia
YOUR LOGO
Flagyl, aka. metronidazole (pill or suspension) – 250mg to 750mg 3x/day for 10 to 14 days. Cyclical dosing is an option.
Vancomycin, aka. vancocin (oral) – 125mg to 750mg 3x/day for 10 to 14 days. Cyclical dosing is an option.
NOTE: Approximate dosing range for both is 20mg to 30mg/kg divided dosages three times daily. On average = 25mg/kg/day.
Cyclical Dosing Options:• One dose TID for 10 days, then every 3rd day – one
treatment day (one dose TID) for 3 weeks. OR• One dose TID every other day for 4 to 6 weeks
Clostridia – Antibiotic Treatment
YOUR LOGO
• Mostly used as an intravenous antibiotic against gram positive bacteria that have resistance to other antibiotics:• Methicillin-resistance Staph aureus.
• Early reports of high rate of kidney and hearing toxicity secondary to IV use seemed to be related to impurities.
• Vancocin is the oral antibiotic for Pseudomembranous colitis and C. difficile associated diarrhea.• Also, enterocolitis from Staph aureus.
Pediatric Dosing (less than 18 years of age): 30mg to 35mg mg/kg in 3 to 4 divided dosages for 7 to 10 day – not to exceed
2 grams (2000mg) in 24 hour period of time.
Vancomycin (Vancocin)
YOUR LOGO
• Effective against a number of intestinal pathogens such as: • Fusabacteria, Bacteroides, Clostridia, as well as
Giardia lamblia and Entamoeba histolytica.
• Available in both intravenous and oral route (capsules or oral suspension) Pediatric Dosing: 7.5mg/kg (23mg/kg/d)
every 8 hours (TID) either as capsule or oral suspension.
Flagyl (Metronidazole)
YOUR LOGO
Effect of metronidazole on urine HPHPA levels in autismWilliam Shaw Nutritional Neuroscience 2010 Vol 13 No 3: 1-10
-50
0
50
100
150
200
250
300
350
400
450
500
0 20 40 60 80 100 120
Days after start of treatment
Uri
ne
HP
HPA
m
mo
l/m
ol c
reat
inin
e Start metronidazole
Stopmetronidazole
YOUR LOGO
Alternative treatments for Clostridium difficile disease: what really works? Lynne V. McFarland Journal of Medical
Microbiology (2005), 54, 101–111
125 mg–500 mg every 3 days over a
meanof 27 days
YOUR LOGO
Using Botanicals Against Clostridia
Case Examples of Reduction and Elimination of Clostridia Toxins and One Apparent
Failure To Treatment
YOUR LOGO
1/9/13
8/5/2013
Vanco x 10 days + Diflucan x 30 days
Biocidin + Culturelle x 60 days
Ex: #1
YOUR LOGO
11/4/13
• Biocidin (2 capsules TID) x 14 days, then every 3rd day for additional 4 weeks did another treatment day of Biocidin (same dose).
• Culturelle – 4 capsules at bedtime
NOTE: discussed with parents if program didn’t work we would need re-implement a longer antibiotic program.
YOUR LOGO
12/19/2013
3/25/2014
YOUR LOGO
6/27/14
• Biocidin (8 drops TID) x 14 days, then every 3rd day for additional 4 weeks did another treatment day of Biocidin (same dose).
• Grapefruit Seed Extract (3 drops TID) every day• Culturelle – 4 capsules at bedtime
Ex: #2
4-cresol – very high
YOUR LOGO
10/21/14
YOUR LOGO
Additional OAT Results on Two Children (Before and After
Botanical Remedies)
YOUR LOGO
Example #1
YOUR LOGO
Program
• Biocidin – 8 drops TID for 14 days, then every 72 hours did another treatment day (of 8 drops TID) for additional 4 weeks.
• Culturelle – 4 capsules at night 90 minutes away from last dose of Biocidin.
• Retested Microbial Organic Acids Test during the last week of Biocidin program.
YOUR LOGO
YOUR LOGO
Example #2 - History of strong negative reaction to Culturelle
YOUR LOGO
Child with history of negative reaction to Culturelle
• Biocidin – 5 drops TID every other day for 6 weeks.
• Ther-Biotic Complete – ¼ teaspoon nightly 90 minutes away from last dose of Biocidin.
• Repeat Organic Acids Test in 6 weeks during the last week of Biocidin use.
YOUR LOGO
Parent decided not to implement program
YOUR LOGO
USP Effectiveness Testing of Biocidin®
Demonstrates inhibitory activity of against both gram positive and gram negative bacteria, yeast and fungus.
Bilberry extract, Grape Seed extract, Milk
Thistle, Echinacea, Goldenseal, Shiitake,
White Willow, Garlic, Black Walnut (hull
and leaf), Raspberry, Fumitory, Gentian,
Noni, Tea Tree oil, Galbanum oil,
Lavender oil, Oregano oil
YOUR LOGO
Rheumatoid Arthritis and Clostridia
A Difficult Case of a Persistent Infection
YOUR LOGO
3/18/14
53 year old female with
diagnosis of Rheumatoid
Arthritis.
Test prior to intervention
4-cresol = 80
YOUR LOGO
In addition to pathogen intervention
• Patient on strict gluten-free and allergen-free diet
• Nutritional supplementation, i.e. antioxidants, probiotics.
• Low Dose Naltrexone (www.lowdosenaltrexone.org)
1. Clinical course overtime has been difficult with periods of partial remission followed by intense exacerbation of symptoms.
2. It was felt that clostridia and subsequent bowel toxicity where a contributing factor to ongoing health issues with RA.
YOUR LOGO
4/17/13
4-cresol – 0.15
3 Weeks after Flagyl
YOUR LOGO
5/31/13
Notice 4-cresol still
normal, but now
HPHPA high
YOUR LOGO
8/14/13
Implemented Flagyl
again, but this time
not successful.
Having intolerance
to antibiotics
YOUR LOGO
11/14/13
Biocidin implemented
for approximately
3 months.
4-cresol still
normal
YOUR LOGO
General OAT Recommendations
• Obtain initial Organic Acids Test or Microbial Organic Acids Test to obtain baseline of clostridia markers.
• Initiate antimicrobial therapy (botanical and/or medication) based on clinical presentation of patient.
• If doing just 10 days of antibiotics, retest OAT or mOAT 2 weeks after regimen completed, and again 1 to 2 months later.
• If doing extended cyclical program, retest OAT or mOAT during the last week of therapy, and then again 1 to 2 months later.
YOUR LOGO
Clostridia Treatment Suggestions• If using antibiotics (Vancocin or Flagyl) use
something daily for yeast too: • Nystatin
• Diflucan
• Botanical, i.e. Biocidin, GSE, Allicin, Yeast Control Packet
• If using botanical remedies as primary clostridia intervention, then consider additional antifungal medication based on severity of candida, i.e. mild/sensitive, moderate, severe.
• In many circumstances the botanicals used for clostridia will also treat the yeast.
YOUR LOGO
Clostridia Treatment Suggestions
• Recommend to use antibiotic (Vancocin or Flagyl) along with Nystatin or Diflucan:• Initiate one versus the other for at least 72 hours
• Minimally use antimicrobial botanical for yeast control.
• The higher the level of HPHPA or 4-cresol, or the combination of clostridia markers, should dictate intensity of program, i.e. antibiotics or combination of different botanicals – association with patients clinical presentation and history.
YOUR LOGO
Clostridia Treatment Suggestions
• The presence of high clostridia markers in association with elevated HVA indicates a more significant impact on Dopamine-Beta Hydroxylase.
• Child who is aggressive, self-injurious or with bowel issues (i.e. loose stools), and with high HPHPA and/or 4-cresol markers, consider antibiotic intervention if possible.
• Use some type of probiotic against clostridia even while using antibiotics.
YOUR LOGO
ProbioticsEmphasis on probiotics with known
specificity against clostridia bacteria (helpful against candida too)
YOUR LOGO
YOUR LOGO
Lactobacillus rhamnosus
• Produces multiple peptidases which help to breakdown gluten and casein peptides.
• Wide-spread adherence within colon to suppress pathogenic E. coli.
• Antagonistic against rotavirus and Clostridium difficile.
• Ex: ProBio Premium, ProBiotic Support Formula, Ther-Biotic Complete, Therelac, Probiotic Infant Formula, Culturelle.
YOUR LOGO
Lactobacillus plantarum
• Helps with induction of interleukin-12 for central immune regulation.
• Decreases production of inflammatory mediators
• Supports intestinal barrier function
• Reduces translocation of gut bacteria
• Antagonizes C. difficile
• Ex: ProBio Premium, ProBiotic Support Formula, Ther-Biotic Complete, VSL#3.
YOUR LOGO
Lactobacillus paracasei
• Ferments inulin to produce high levels of lactic acid
• Contributes to a healthy vaginal microflora
• Has supportive benefit in conditions ranging from allergic rhinitis to non-rotavirus diarrhea in children.
• Antagonizes C. difficile, Staphylococcus aureus, and other pathogens.
• Ex: ProBio Premium, ProBiotic Support Formula, Ther-Biotic Complete, Therelac, VSL#3, Probiotic Infant Formula.
YOUR LOGO
Bifidobacterium bifidum
• Present in large numbers in a healthy colon
• Suppresses total and antigen-specific IgE production
• Enhances IgM and IgG responses to select antigens
• Activates B cell IgA secretion
• Enhances IgA response to C. difficile toxin A. Along with L. acidophilus, supports gut microflora during antibiotic therapy and reduces positive testing for C. difficile toxins.
• Ex: ProBio Premium, ProBiotic Support Formula, Ther-Biotic Complete, Probiotic Infant Formula.
YOUR LOGO
Bifidobacterium breve
• Stimulates Peyer’s patch B cell proliferation and antibody production.
• Eliminates stool Campylobacter jejuni in campylobacter enteritis helping to restore normal intestinal flora.
• Secretes various compounds favorable to modify intestinal microflora by reducing Bacteroides and Clostridium concentrations.
• Ex: Ther-Biotic Complete, VSL#3, Probiotic Infant Formula.
YOUR LOGO
Lactobacillus gasseri
• Native to the human gut and vaginal tracts of healthy women and normally present in human breast milk.
• Protects against intestinal mitogens and carcinogens.
• Produces hydrogen peroxide and bacteriocinsinhibitory to Clostridium, Listeria, and Enterococcus.
• Ex: Probiotic Infant Formula
YOUR LOGO
Bifidobacterium lactis
• Enhances leukocyte tumor cell-killing properties and phagocytic activity.
• Increases numbers of total, helper, and activated T cells.
• Significantly increases serum and mucosal IgA production to cholera toxin and Clostridium tetanus toxoid.
• Ex: ProBio Premium, ProBiotic Support Formula, Ther-Biotic Complete, Therelac, VSL#3, Probiotic Infant Formula.
YOUR LOGO
Saccharomyces boulardii
• Augments colon bifidobacterium populations and increases butyrate concentrations.
• Enhances brush border enzyme activities and improves gut barrier function.
• Antimicrobial yeast with activities against C. difficile, toxigenic E. coli, Candida, and other gastrointestinal pathogens.
• Ex: ProBiotic Support Formula, or individual S. boulardii supplement.
YOUR LOGO
Probiotic Infant Formula
¼ teaspoon = 10 billion CFU’s – Infant up to age 2
YOUR LOGO
High Dose Probiotics
2 capsules = 225 billion CFUs 1 packet = 225 billion CFUs
YOUR LOGO
Culturelle – Acidophilus GG, aka. L. Rhamnosus
1 capsule = 10 billion CFU
YOUR LOGO
Multi-Flora Probiotics
1 capsule equals approximately 25 billion CFUs
YOUR LOGO
Saccharomyces boulardii
1 capsule = 3 billion CFUs
YOUR LOGO
• Culturelle – anti-clostridia
• VSL#3 – anti-clostridia and high oxalates
• Pro-Bio Premium – re-establish gut flora, some activity against clostridia. High oxalates.
• ProBiotic Support Formula – re-establish gut flora, some activity against clostridia and yeast.
• Klaire Ther-Biotic Complete – re-establish gut flora, some activity against clostridia and yeast.
• Probiotic Infant Formula – positive activity against clostridia, re-establish flora for under and 2 years of age.
• Saccharomyces boulardii – anti-yeast and anti-clostridia
Treatment Specific Uses
YOUR LOGO
Fecal Microbiota Transplant (FMT)
• Defined as: Infusion of a fecal suspension from a healthy individual into the gastrointestinal tract of another person to cure a specific disease (Brandt LJ,
Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78:240-249)
• FMT has an approximate 90% cure rate for patients with recurrent Clostridium difficile infection (CDI).
• Some researchers feel that it is the most effective treatment available for this CDI, far surpassing that of antibiotics.
YOUR LOGO
Fecal Microbiota Transplant
• The procedure can be done using fresh stool transplants, frozen stool transplants (capsules are a subtype), or biosynthetic combinations of organisms derived from normal fecal microbiota.
• CDI is defined in the American College of Gastroenterology (ACG) guidelines as "acute onset of diarrhea with documented toxigenic C. difficile or its toxin and no other documented cause for diarrhea.” (Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498.)
YOUR LOGO
ACG guidelines for C. difficile
For an initial case of CDI, the ACG recommends
1. Discontinue the contributing antimicrobial agent and treat mild to moderate cases with Metronidazole.
2. For severe CDI, or for patients not responding to Metronidazole, the ACG recommends Vancomycin.
3. Recommended treatment for a first recurrence of CDI is to repeat the regimen used for the initial episode unless the CDI is severe, in which case the patient should be switched to Vancomycin.
4. For a second recurrence, the ACG recommends a pulsed Vancomycin regimen.
5. For a third recurrence after this, the ACG recommends considering FMT.
YOUR LOGO
Infectious Diseases Society of America
See handout: Fecal Transplant Donor Test Recommendations
YOUR LOGO
Other Online Support Organizations
• The Power of Poop – www.powerofpoop.com
• Resource links for instructions on rectal fecal transplant and fecal transplant capsules, plus additional information.
• Fecal Microbiota Transplantation –www.fmt.gastro.org• Resource with information on testing, referral doctors,
research, etc.
• Open Biome - www.openbiome.org• Non-profit stool bank
• Assists doctors in obtaining prescreened fecal samples
YOUR LOGO
Topic
• “Small Intestine Bacterial Overgrowth (SIBO) –Clinical Issues, Diagnostic Testing and Treatment Options”• The role of Small Intestine Bacterial Overgrowth (SIBO) in
gastrointestinal problems.
• The pathogenicity of SIBO
• Common diagnostic tests for SIBO
• Using the Organic Acids Test in the assessment of SIBO
• Treatment options using antibiotic and natural remedies
Module #6
Thank YouKurt N. Woeller, D.O. & Tracy Tranchitella, N.D.
www.GIMasteryCourse.com